Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Scleroderma--clinical and pathological advances.

Christopher P Denton1, Carol M Black

  • 1Centre for Rheumatology, Royal Free Hospital, Pond Street, London, NW3 2QG, UK. c.denton@rfc.ucl.ac.uk

Best Practice & Research. Clinical Rheumatology
|May 26, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physician-patient communication in the treatment of systemic sclerosis-associated interstitial lung disease: A narrative review and recommendations.

Journal of scleroderma and related disorders·2025
Same author

Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic Sclerosis.

ACR open rheumatology·2025
Same author

Guidance for stem cell therapy for juvenile systemic sclerosis patients.

Expert review of clinical immunology·2025
Same author

Publisher Correction: An international perspective on the future of systemic sclerosis research.

Nature reviews. Rheumatology·2025
Same author

An international perspective on the future of systemic sclerosis research.

Nature reviews. Rheumatology·2025
Same author

Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based study.

Seminars in arthritis and rheumatism·2025
Same journal

The young adult with Juvenile Idiopathic Arthritis (JIA): A clinical review of transition, complications, and psychosocial management.

Best practice & research. Clinical rheumatology·2026
Same journal

Impact of fatigue on rheumatic diseases: Current perspectives.

Best practice & research. Clinical rheumatology·2026
Same journal

Pneumocystis prophylaxis in rheumatic disease.

Best practice & research. Clinical rheumatology·2026
Same journal

Cutaneous manifestations in myositis syndromes.

Best practice & research. Clinical rheumatology·2026
Same journal

Systemic sclerosis: A comprehensive systematic review of global epidemiology, sex and ethnic disparities, disease burden, and organ-specific involvement.

Best practice & research. Clinical rheumatology·2026
Same journal

Alopecia across the spectrum of rheumatic disease.

Best practice & research. Clinical rheumatology·2026
See all related articles

Scleroderma management has advanced significantly, improving outcomes for organ complications and offering new disease-modifying treatments. Future clinical trials promise to further transform systemic sclerosis care.

Area of Science:

  • Rheumatology
  • Immunology
  • Dermatology

Background:

  • Scleroderma encompasses a spectrum from Raynaud's phenomenon to systemic sclerosis (SSc).
  • Recent advances have refined SSc classification, natural history understanding, and organ-specific complication management.
  • SSc involves complex inflammatory, vascular, and fibrotic pathologies.

Purpose of the Study:

  • To review recent advancements in scleroderma (systemic sclerosis) classification, natural history, and organ-based complication management.
  • To highlight progress in understanding SSc pathogenesis and treatment.
  • To discuss new disease assessment tools and future therapeutic prospects.

Main Methods:

  • Review of current literature on scleroderma and systemic sclerosis.

Related Experiment Videos

  • Analysis of recent changes in disease classification and natural history.
  • Examination of therapeutic advances for organ-specific complications (renal, pulmonary, gastrointestinal).
  • Discussion of novel assessment tools and emerging treatments.

    • Main Results:

    • Significant improvements in managing renal and pulmonary complications of SSc.
    • Effective treatments identified for gastrointestinal issues, scleroderma renal crisis, and pulmonary arterial hypertension.
    • Development of tools for assessing skin biomechanics, functional impairment, and disease activity.
    • Emerging targeted therapies offer potential for disease modification in early SSc.

    Conclusions:

    • Scleroderma management has substantially improved, with better outcomes for organ complications.
    • New treatments and assessment tools are transforming systemic sclerosis care.
    • Future clinical trials are expected to further revolutionize SSc treatment, challenging its previously intractable reputation.